{"id":827962,"date":"2025-03-20T08:07:16","date_gmt":"2025-03-20T12:07:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"modified":"2025-03-20T08:07:16","modified_gmt":"2025-03-20T12:07:16","slug":"vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","title":{"rendered":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BRIDGEWATER, N.J., March  20, 2025  (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in the H.C. Wainwright 3<sup>rd<\/sup> Annual Autoimmune &amp; Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025.<\/p>\n<p align=\"justify\">\n        <strong>Conference Presentation Details:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:70%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;text-align: left;vertical-align: middle;vertical-align: top\">Fireside Chat Timing:<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;text-align: left;vertical-align: middle;vertical-align: top\">Thursday, March 27, 2025, at 11:00 am ET<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Registration:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"https:\/\/journey.ct.events\/view\/ab5ad5ce-0584-4a6b-8efa-ddcdb32b1ce4\" rel=\"nofollow\" target=\"_blank\">Webcast Link<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">A webcast replay will be available on the VYNE website for 90 days following the event.\u00a0\u00a0<\/p>\n<p align=\"left\">\n        <strong>About VYNE Therapeutics Inc.<\/strong><br \/>\n        <br \/>VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE&#8217;s unique and proprietary BET inhibitors, which comprise its InhiBET\u2122 platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.<\/p>\n<p>For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE\u2019s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), public conference calls, and webcasts.<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>John Fraunces<br \/>LifeSci Advisors, LLC<br \/>917-355-2395<br \/><u>jfraunces@lifesciadvisors.com<\/u><\/p>\n<p>\n        <strong>Tyler Zeronda<\/strong><br \/>\n        <br \/>VYNE Therapeutics Inc.<br \/>908-458-9106<br \/><u>Tyler.Zeronda@VYNEtx.com<\/u><\/p>\n<p>\n        <strong>Media Relations: <\/strong><br \/>\n        <br \/>Mike Beyer<br \/>Sam Brown Inc.<br \/>312-961-2502<br \/><u>mikebeyer@sambrown.com <\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGVjN2YxMGItYmI3MC00NDI4LWJhYzctM2UxZTFiMmQ5MTgzLTExMDUzNzQtMjAyNS0wMy0yMC1lbg==\/tiny\/VYNE-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025. Conference Presentation Details: Fireside Chat Timing: Thursday, March 27, 2025, at 11:00 am ET Registration: Webcast Link \u00a0 A webcast replay will be available on the VYNE website for 90 days following the event.\u00a0\u00a0 About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827962","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025. Conference Presentation Details: Fireside Chat Timing: Thursday, March 27, 2025, at 11:00 am ET Registration: Webcast Link \u00a0 A webcast replay will be available on the VYNE website for 90 days following the event.\u00a0\u00a0 About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat &hellip; Continue reading &quot;VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T12:07:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\",\"datePublished\":\"2025-03-20T12:07:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"name\":\"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\",\"datePublished\":\"2025-03-20T12:07:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","og_description":"BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 27, 2025. Conference Presentation Details: Fireside Chat Timing: Thursday, March 27, 2025, at 11:00 am ET Registration: Webcast Link \u00a0 A webcast replay will be available on the VYNE website for 90 days following the event.\u00a0\u00a0 About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat &hellip; Continue reading \"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T12:07:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference","datePublished":"2025-03-20T12:07:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","name":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=","datePublished":"2025-03-20T12:07:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzU4OCM2ODE1MDk4IzIwOTM4MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VYNE Therapeutics to Participate in the H.C. Wainwright\u00a03rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827962"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827962\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}